Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2021 | Novel approaches to treating AML in elderly patients

Tapan Kadia • 26 Aug 2021
SOHO 2021
Acute Myeloid Leukemia Leukemia Cladribine Cytarabine Decitabine Venetoclax

Tapan Kadia, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of the treatment options for acute myeloid leukemia (AML) in elderly patients, as well as explaining how treatment differs between ages. Dr Kadia talks on the promising response rates demonstrated by the BCL-2 inhibitor venetoclax in combination with hypomethylating agents. Additionally, Dr Kadia talks on the use of double nucleoside analog therapy of cladribine and low-dose cytarabine alternating with decitabine as a backbone treatment to allow for further novel combinations. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Tapan Kadia

Updates on established therapies in AML
19:03
Updates on established therapies in AML
Jessica Altman et al. • 20 Sep 2025
CLIA (cladribine, idarubicin, and cytarabine) plus venetoclax in newly diagnosed AML
2:35
CLIA (cladribine, idarubicin, and cytarabine) plus venetoclax in newly diagnosed AML
Tapan Kadia • 8 Dec 2024
Cladribine with low-dose cytarabine & venetoclax alternating with azacitidine & venetoclax in AML
2:47
Cladribine with low-dose cytarabine & venetoclax alternating with azacitidine & venetoclax in AML
Tapan Kadia • 8 Dec 2024
Pegfilgrastim improves outcomes of intensive chemotherapy plus venetoclax in newly diagnosed AML
2:34
Pegfilgrastim improves outcomes of intensive chemotherapy plus venetoclax in newly diagnosed AML
Tapan Kadia • 8 Dec 2024

Related Videos

Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
4:04
Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
Anna Schuh • 16 Oct 2026
Understanding the CLL genome: current knowledge and remaining gaps
3:39
Understanding the CLL genome: current knowledge and remaining gaps
Anna Schuh • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals